Science Applications International Corp
SAICScience Applications International Corporation, Inc. (SAIC) is an American technology company headquartered in Reston, Virginia that provides government services and information technology support.
Drugs in Pipeline
12
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Mar 15, 2026
5wMarket Overview
Stock performance and market intelligence
1 upcoming, 0 past
Progerinin Phase 2 Results Expected
Primary completion for Progerinin trial (NCT06775041) in Hutchinson-Gilford Progeria Syndrome
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
MY008211A tablets
Paroxysmal Nocturnal Hemoglobinuria
SST-0225
Delayed Onset Muscle Soreness, DOMS
SJP-0132
Dry Eye
VPM1002
Infection, Respiratory Tract
Next Science Acne Gel
Acne Vulgaris
wSp vaccine
Acute Otitis Media (AOM)
BCG
Tuberculosis
Progerinin
Hutchinson-Gilford Progeria Syndrome
rSIFN-co Nasal Spray
COVID-19
Sildenafil Cream
Erectile Dysfunction
QR052107B 100 mg
Cough
SST-6007
Sexual Arousal Disorder
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
MY008211A tablets | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - |
SST-0225 | Phase 3 | Delayed Onset Muscle Soreness, DOMS | - |
SJP-0132 | Phase 3 | Dry Eye | - |
VPM1002 | Phase 3 | Infection, Respiratory Tract | - |
Next Science Acne Gel | Phase 2 | Acne Vulgaris | - |
wSp vaccine | Phase 2 | Acute Otitis Media (AOM) | - |
BCG | Phase 2 | Tuberculosis | - |
Progerinin | Phase 2 | Hutchinson-Gilford Progeria Syndrome | - |
rSIFN-co Nasal Spray | Phase 2 | COVID-19 | - |
Sildenafil Cream | Phase 2 | Erectile Dysfunction | - |
QR052107B 100 mg | Phase 2 | Cough | - |
SST-6007 | Phase 2 | Sexual Arousal Disorder | - |
Regulatory & News
Approvals, filings, and latest developments